Cure My Disease

Don't miss your cure!

 Log in / Sign up

Uric acid levels may predict pancreatic cancer survival

NCT ID NCT07091526

Knowledge-focused Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks back at 168 pancreatic cancer patients who had surgery to remove their tumor. Researchers want to see if changes in uric acid levels after surgery are linked to how long patients live and whether the cancer comes back. The goal is to find out if controlling uric acid could improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 168 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Radical pancreatic cancer resection patients

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with pathologically confirmed pancreatic cancer (primary) * Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy） * The postoperative survival time was at least 6 weeks Exclusion Criteria: * No surgery was performed, or only palliative surgery/ biopsy was performed * Patients who underwent emergency hemodialysis or plasma exchange after surgery * History of gout or long-term urate-lowering therapy, such as allopurinol * Patients are missing follow-up data * Hydrochlorothiazide and furosemide were used * Chronic kidney disease * Oncolytic syndrome * Hemolytic anemia * Lead poisoning * Hyperparathyroidism * Hypothyroidism * A tyrosinase inhibitor was used * Patients with nonpancreatic primary tumors * Pregnant or postpartum women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Serum uric acid

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hepatopancreatobiliary Surgery Institute of Gansu Province

    RECRUITING

    Lanzhou, Gansu, 730000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.